Altana buys GlaxoSmithKline's U.S. dermatology business

New York, Sept. 30 - Altana Pharma AG said its Altana inc. subsidiary acquired the prescription dermatology business from GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline Corp.

Altana Inc.'s PharmaDerm division will manufacture and market the former GlaxoSmithKline products, including Aclovate (alclometasone dipropionate), a synthetic corticosteroid, Cutivate (fluticasone propionate), an anti-inflammatory, Emgel (erythromycin), an antibiotic, Oxistat (oxiconazole nitrate), an anti-fungal and Temovate (clobetasol propionate), an anti-inflammatory.

"This transaction represents a key acquisition on the branded side of our business and supports the Altana Inc. specialty business. It is a significant step in the formation of PharmaDerm and toward achieving our goal of becoming the leading pharmaceutical company specializing in dermatology," said Paul B. McGarty, chief executive officer of Altana Inc., in a news release.

PharmaDerm is a specialty pharmaceutical manufacturer specializing in topical dermatological prescription products and headquartered in Atlanta. Altana Inc. is headquartered in Melville, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.